Damora Therapeutics, Inc. Ordinary Shares
DMRA
11 hedge funds and large institutions have $442K invested in Damora Therapeutics, Inc. Ordinary Shares in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.05% more ownership
Funds ownership: 10.76% → 10.81% (+0.05%)
33% less capital invested
Capital invested by funds: $661K → $442K (-$218K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.46K |
| 3 |
Renaissance Technologies
New York
|
+$1.41K |
| 4 |
Squarepoint
New York
|
+$1.33K |
| 5 |
Barclays
London,
United Kingdom
|
+$627 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$57.4K |
| 2 |
JP Morgan Chase
New York
|
-$466 |
| 3 |
Morgan Stanley
New York
|
-$465 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NHAS
1
Novo Holdings A/S
Hellerup,
Denmark
| $310K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $47.6K | +$1.41K | +300 | +2% |
|
|
3
Squarepoint
New York
| $40.3K | +$1.33K | +283 | +2% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $33.2K | +$50.5K | +10,722 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.91K | +$7.46K | +1,583 | New |
|
6
Bank of America
Charlotte,
North Carolina
| $3.8K | – | – | – |
|
7
BlackRock
New York
| $1.52K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $883 | -$57.4K | -12,182 | -98% |
|
|
9
Barclays
London,
United Kingdom
| $412 | +$627 | +133 | New |
|
|
SS
10
SBI Securities
Tokyo,
Japan
| $56 | – | – | – |
|
11
Group One Trading
Chicago,
Illinois
| $9 | – | – | – |
|
|
12
JP Morgan Chase
New York
| – | -$466 | -100 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$465 | -100 | Closed |
|
DMRA Hedge Fund Activity: Q1 2025 in Review
11 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2025, worth a combined $442K — down 33% from $661K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DMRA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $50.5K. The largest seller was UBS Group, cutting an estimated $57.4K.
- 11 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2025, up from 10 in Q4 2024.
- Funds reported $442K of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2025, down 33% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2025 was Susquehanna International Group, an estimated $50.5K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2025 was UBS Group, an estimated $57.4K sold.
Based on aggregated 13F filings for Q1 2025.